Shots:

• The P-III POLARIX trial evaluates the efficacy- safety- and PK of Polivy + R-CHP vs R-CHOP in 879 patients in a ratio (1:1) with previously untreated DLBCL for 6 cycles- followed by Rituxan for 2cycles; or R-CHOP + Polivy PBO for 6 cycles- followed by 2 cycles of Rituxan. The trial is being conducted in collaboration with LYSA & LYSARC
• The trial met its 1EPs that demonstrating the improvement in PFS. Additionally- the safety results were consistent with previous trials. The results will be submitted to health authorities globally
• Polivy is currently used as an off-the-shelf- FD treatment option and approved in combination with bendamustine and Rituxan for R/R DLBCL in 60+ countries globally- including in the EU & US

| Ref: Businesswire | Image: Xconomy